Medistem Laboratories Inc., the company whose researchers published the recent stem cell treatment proposal in the Journal of Translational Medicine has applied for a patent in respect of its stem cell therapy which covers patient selection, therapeutic combinations and various stem cell types. Hopefully the patent, if granted, promotes further research and development in this area, and if the treatment is proven effective and beneficial to autistic patients, does not render the price of treatment beyond reach for generations.
Medistem Announces Autism Stem Cell Therapy Paper and Filing of IP Aug 1 2007, 5:05 AM EST MARKETWIRE Aug 01, 2007 SCOTTSDALE, AZ MARKET WIRE Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U) announced today the filing of IP and publication of a peer reviewed paper describing a novel method of selecting specific subsets of autistic patients for treatment with a combination of cellular therapies. "Based on positive case report data from one of our licensees, Medistem plans to explore the possibility of seeking regulatory approval in the U.S. for a Phase I clinical trial involving our novel stem cell therapeutic methods for treatment of autism," said Neil Riordan PhD, President and CEO of Medistem. He continued, "We are at the stage where a patent application has been filed, we've announced the scientific basis for our program in a peer reviewed journal, and now we are seeking and initiating discussions with clinical collaborators and patient interest groups in the U.S." Medistem published a paper entitled "Stem Cell Therapy for Autism" in the Journal of Translational Medicine that is freely available online at http://www.translational-medicine.com/content/pdf/1479-5876-5-30.pdf. A video summary of the paper may be seen at http://www.youtube.com/watch?v=FlSaXCzLW6w Thomas Ichim, Medistem's Chief of Scientific Development and primary author on the paper, stated, "Given the staggering incidence of autism in the U.S. (approximately 1 in 166), and the lack of viable treatment options, we believe that our IP in this area will not only allow for internal product development, but also enable Medistem to seek collaboration with other companies that have approval for using stem cells in the U.S. under clinical trial exemptions." Medistem has numerous patent applications filed in the area of stem cell expansion, composition of matter, and therapeutic use. The patent application entitled "Stem Cell Therapy for Autism" covers patient selection, therapeutic combinations, and various stem cell types for the treatment of autism. About Medistem Laboratories, Inc. Medistem Laboratories is a biotechnology company that discovers, develops, and commercializes adult stem cell products that address serious medical conditions. While drug discovery and development is its primary focus, Medistem has compiled a body of proprietary technologies it outlicenses to commercial entities in markets where stem cell administration is permissible. Due to its licensee relationships and collaborative efforts with respected institutions, Medistem believes it is well positioned to be a leading developer of adult stem cell products. Cautionary Statement This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs. These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission. Contact: Medistem Laboratories, Inc. Chris McGuinn 602-318-3535 http://www.medisteminc.com
http://www.genengnews.com/news/bnitem.aspx?name=21104666 SOURCE: Medistem Laboratories
Derek Kravitz on Measles in Washington Post
1 hour ago
